
Heatwaves are making nights warmer than ever: Why it's dangerous for our health
A new study has revealed that nearly 76% of India's population is now living in districts marked as "high" or "very high" heat risk zones.The report, released by Delhi-based think tank Council on Energy, Environment and Water (CEEW), highlights the increasing danger caused by extreme heat and humidity across the country.The study, which assessed 734 districts using 40 years of climate data (1982–2022), found that 417 districts, which is more than half of India, are under high to very high heat risk.advertisement
These include major states and union territories like Delhi, Maharashtra, Goa, Kerala, Gujarat, Rajasthan, Tamil Nadu, Andhra Pradesh, Madhya Pradesh, and Uttar Pradesh.NIGHTS BECOMING HOTTER THAN DAYSWhile daytime temperatures continue to rise, the report also found that very warm nights, when minimum temperatures exceed the 95th percentile of historical norms, are increasing even faster than very hot days.This has serious implications for health.
While daytime temperatures continue to rise, the report also found that very warm nights, when minimum temperaturesexceed the 95th percentile of historical norms, are increasing even faster than very hot days. (Photo: Reuters)
High night temperatures can be more dangerous because the body doesn't get a chance to cool down after daytime heat exposure.advertisement"The rise in very warm nights is most noticeable in districts with a large population," the study noted, citing cities like Mumbai, Bengaluru, Bhopal, Jaipur, Delhi, and Chennai, where summer nights have become significantly hotter over the past decade.IMPACT OF HEAT ON HEALTHDoctors have warned that prolonged exposure to high heat and humidity is taking a visible toll on people's health."We are seeing a spike in cases of persistent headaches, dizziness, fatigue, muscle cramps, dehydration, and poor sleep quality," said Dr. Arunesh Kumar, Senior Consultant, Respiratory Medicine, Paras Health, Gurugram.People with chronic conditions like asthma are particularly vulnerable, since the heavy, moisture-laden air can worsen respiratory discomfort.
Doctors have warned that prolonged exposure to high heat and humidity is taking a visible toll on people's health. ()
High humidity also interferes with the body's natural cooling mechanism by limiting the evaporation of sweat, which leads to overheating and increases the risk of heat exhaustion or even heatstroke.The CEEW study further found that summer humidity in northern parts of the country has climbed from 30-40% to 40-50% in the last decade, making early mornings feel warmer and worsening heat stress, especially for outdoor workers in the Indo-Gangetic plain.advertisementRECORD-BREAKING TEMPERATURES AND EARLY HEATWAVESThe year 2024 was the hottest on record in India and worldwide, and 2025 isn't far behind.The country experienced its first heatwave this year as early as February 27–28, more than a month earlier than the previous year.According to the World Health Organisation, over 1.66 lakh people died globally due to heatwaves between 1998 and 2017.
According to the World Health Organisation, over 1.66 lakh people died globally due to heatwaves between 1998 and 2017. ()
In India alone, over 48,000 heatstroke cases and 159 deaths were reported in 2023, although experts believe the actual numbers are likely higher.HEATSTROKE HAS LONG-TERM EFFECTSHeatstroke is often viewed through a narrow lens: a medical emergency requiring quick hydration and cooling.But this dangerous condition doesn't end when the fever breaks or the pulse stabilises, according to Dr. Vikram Vora, Medical Director, International SOS.advertisement"What it leaves behind, both mentally and physically, can quietly compromise an individual's ability to work, focus, and live well," Dr. Vora told IndiaToday.In.Dr. Vora added that many survivors suffer from fatigue, chronic dehydration, muscle cramps, and even cognitive issues like memory loss or difficulty concentrating.This has major implications for workers in both outdoor and indoor settings.
Heatstroke is often viewed through a narrow lens: a medical emergency requiring quick hydration and cooling. (Photo: PTI)
"Over time, the psychological strain of working in relentless heat, or the trauma of having experienced heatstroke, can lead to chronic anxiety, irritability, and depression. Workers report feelings of dread before each shift, knowing what's in store," he said.He recommended that employers invest in shaded break zones, water stations, and restrooms, and include heat-exposed workers in mental health and wellness programs.HOW TO STAY SAFE FROM HEATSTROKEAs temperatures soar, the risk of heatstroke also increases.Dr RS Mishra, principal director, internal medicine at Fortis Hospital, outlined key strategies to prevent heat-related illnesses:advertisementStay hydrated with water and electrolyte-rich drinks.Wear light, breathable clothing and use accessories like hats and sunglasses.Avoid outdoor activity during peak sun hours (10 am – 4 pm).Take frequent breaks if working outside, and stay in the shade.Know the symptoms of heatstroke, like dizziness, cramps, and confusion, and seek immediate help if they occur.Use cooling methods such as fans, cold showers, or wet clothes on pulse points.Eat light, water-rich foods and monitor at-risk groups like the elderly and children.As India battles growing heat stress, both individuals and policymakers will need to take urgent action to adapt and protect public health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
5 hours ago
- Time of India
Doctors develop new light-based treatment for rare eye infection
Hyderabad: Doctors at the LV Prasad Eye Institute in Hyderabad have discovered a new way to treat a rare but serious eye infection called acanthamoeba keratitis (AK) — a rare but serious eye infection that causes pain, redness, and can lead to vision loss. Tired of too many ads? go ad free now This infection is caused by amoeba found in places like water and soil. According to the study, it mostly affects people who wear contact lenses or come into contact with dirty water, such as those working on farms or using tap water to clean their lenses. Doctors tested a new light-based treatment called photodynamic therapy (PDAT-RB) and found it promising. The antimicrobial treatment uses a special dye called rose bengal, which is activated by light to produce powerful molecules that kill the infection. This, in turn, helped reduce inflammation in the eye. Rose bengal is a reddish-pink dye used in the diagnosis of eye conditions, which turned out to act as an effective photosensitising agent. Published in the United Kingdom-based Journal of Ophthalmic Inflammation and Infection, the study states that the most common cause of this disease is exposure of the eyes to contaminated water, especially in agricultural fields or washing contact lenses with tap water. An estimated 30-40% of patients suffering from AK require corneal transplantation, known as keratoplasty, on average. Despite that, many do not regain good visual acuity and require additional surgery. This study included 14 patients with AK infection. At first, they were given regular medicines to treat the infection. Then they received the new light-based PDAT treatment twice a week. The doctors used a solution with 0.1% rose bengal dye as part of the therapy. Tired of too many ads? go ad free now Doctors found that the treatment with the PDAT-RB reduced the need for corneal transplantation in 72% of the total patients with bacterial keratitis (inflammation of the cornea). Moreover, the infection was cleared in about 86% of patients within two to five months after the treatment. While most patients were suffering from almost complete vision loss before the treatment, only two of the total patients in the study required a corneal transplant to repair the damaged part. Although their vision improved after PDAT-RB therapy, they still had poor sight. On average, their vision went from total blindness to being able to see large objects or movement. Dr Gowtham Lakshminarayan, a research assistant scientist involved in the study, explained that the treatment works by creating powerful chemicals that destroy the harmful organisms in the eye. "The study suggests that if this treatment is used early, it can be a helpful and less-invasive (non-surgical) option to manage a severe eye infection that is usually hard to treat with regular medicines. The new treatment also shows that rose bengal is an effective photosensitiser and that early intervention with PDAT-RB treatment can yield promising results in the AK eye infection," he added.


Time of India
7 hours ago
- Time of India
Hop on to a bicycle and ride your way to weight loss and fitness
Lucknow: When Prabhat Ranjan looked in the mirror at 110 kg, he barely recognised himself. Once a school-level cyclist, the demands of work had long taken him off the saddle. But at 33, alongside his wife Amrita Ranjan, he returned to cycling — and to himself. Tired of too many ads? go ad free now Over time, he lost 35 kg and participated in global events like the Paris-Brest-Paris race. Life dealt him a heavy blow when his wife passed away during a cycling ride, yet the same cycle that brought pain also became his path to healing. "I saw myself in the mirror and realised it wasn't me. After 15 years, I returned to cycling, and it changed my life. I even lost my wife while cycling, but it gave me fitness, fame and emotional strength," said Ranjan, while explaining the benefits of cycling on the eve of World Bicycle Day. Sandeep Joshi, 55, began pedalling after struggling with ulcerative colitis and high blood pressure. What started as a health decision soon became a daily escape and therapy, as he now rides 50-60 km a day. "It controlled my BP, weight and heart issues. Cycling is my biggest stress reliever," said Joshi. Lucknow-based fashion designer Mili Malhotra turned to cycling after arthritis and thyroid complications began affecting her mobility and mood. Watching her mother struggle post-knee surgery, she vowed to write a different story for herself. "My mother was treated like a burden after surgery. I didn't want that. Cycling helped with joint pain and menopause mood swings," she said Deepali, 52, a former runner, had to give up running due to arthritis. Advised to try cycling, she has been riding for five years now, regaining mobility and reducing pain. Cancer survivor Satyam Pandey, 22, found mental and physical recovery through cycling after relapse of Classical Hodgkin Lymphoma (CHL) in 2020. "It's been a lifesaver. Now all my reports are clear," said Pandey Pratima Awasthi, 56, credits cycling for improving both her stamina and mental strength, while 54-year-old Debu Debnath overcame severe knee pain through consistent riding. For theatre artist Bhushan Agarwal, daily rides became the cure for long-term stomach issues. "Cycling helped me recover completely," he said. Shailesh Singh, a bank officer, was suffering from cervical spondylosis and obesity. At 108 kg, he was advised to wear a neck collar indefinitely. He took up cycling with support from the Avengers Cycling Group. Within months, he lost 17 kg and regained his health.


Time of India
8 hours ago
- Time of India
Glenmark's blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow. Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other advanced treatments, such as CAR-T cell therapy and bi-specific antibodies, also showed encouraging results when given the drug. IGI is an alliance between the New York-based scientific research group Ichnos Sciences and Indian drug maker Glenmark. Senior haematologists say that the drug could potentially be an important candidate in the treatment of patients - who exhaust other therapy options due - to its unique mechanism of engaging the body's T cells (that are a vital part of the immune system) along with the attacking two sites on the tumour cell. Dr Shyam Rathi, consultant, clinical hematology, PD Hinduja Hospital & Medical Research Centre in Mumbai, said: 'It can definitely be a game changer in treatment of multiple myeloma which keeps relapsing thus exhausting treatment options quickly. This new drug looks very attractive because it targets two different sites on the cancer cell and it engages the body's own T-cells.' 'We have existing bi-specific antibodies where the target is only one antigen and they develop resistance very fast. However, ISB 2001 targets the two sites on the cancer cell and we expect some better results. It looks exciting in the future.' In lay terms, ISB 2001 binds to three sites on the cancer tumour. First, the ISB 2001 activates the CD-3 T-lymphocytes, which are the cells that have the natural attacking power against tumour cells. Next, it binds to two additional sites. The first is BCMA (a protein found on myeloma cells), which is the target for bi-specific antibodies but there is also CD38, which is the binding site of the widely prescribed drug called daratumumab, branded as Darzalex by Johnson & Johnson. Glenmark, which is pinning a lot of hopes on the new drug, is in advanced talks with multiple global Big Pharma companies for a licensing deal, Chairman and Managing Director Glenn Saldanha told analysts over an earnings call recently. 'The discussions are progressing really well, and we anticipate a positive outcome very quickly,' said Saldhana. He said a deal for ISB 2001 will 'really be transformational for Glenmark' and 'will overshadow anything else that we are doing in the near term.' 'You should see some visibility around a licensing deal pretty quickly.' Last year Ichnos and Glenmark entered into a partnership for discovery of cutting-edge therapies, specifically to treat blood related cancers and malignancies like multiple myeloma. The global market for multiple myeloma treatment is seeing a surge. The business for such drugs is expected to rise to $33 billion by 2030, up from $23.5 billion in 2023,according to Bloomberg Intelligence estimates. Hang Quach, professor of haematology at the University of Melbourne noted that the data presented on ISB 2001 highlighted the 'remarkable anti-myeloma activity of this first-in-class trispecific antibody-T cell engager in heavily pre-treated RRMM patients' including those who have exhausted other approved therapies. According to Quach, ISB 2001 has the potential 'to redefine the treatment landscape for multiple myeloma, offering new hope for patients with limited therapeutic options.' The drug demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported.